Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children

Experience at a single institution

Kuo Liang Chiang, Kai Ping Chang, Yi Yen Lee, Pin I. Huang, Ting Rong Hsu, Yi Wei Chen, Feng Chi Chang, Tai-Tong Wong

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to assess the efficacy of TMZ on diffuse brainstem glioma, either concomitant with radiotherapy or as an adjuvant treatment after radiotherapy in children. Methods and materials: Eighteen children (median age at diagnosis was 8.3 years) meet the following criteria: (1) newly diagnosed diffuse brainstem glioma; (2) aged less than 18 years old, which were treated with TMZ at Taipei Veterans General Hospital from January 2004 to December 2008. They were divided into two groups according to treatment modalities: a radiotherapy alone followed by adjuvant TMZ (RT+TMZ) group received conventional radiation after initial diagnosis, and a concomitant chemoradiotherapy followed by adjuvant TMZ (CCRT+TMZ) group received concurrent chemotherapy during radiation with TMZ (75 mg/M2/day). After completion of the radiotherapy, TMZ (150 mg/M2) was administered once per day for five consecutive days for all enrolled patients in each 28-day cycle. We evaluated the progression-free survival in both groups of patients. Results: There were 10 patients in RT+TMZ group and eight in CCRT+TMZ group. All patients experienced progression of disease. Twelve patients (75%) died, and all deaths were attributed to the disease progression. The median progression-free survival (PFS) was 7.4 months for the RT+TMZ group and 6.4 months for the CCRT+TMZ group. The 6-month and 1-year PFS in the RT+TMZ group were 70% (SD 14%) and 30% (SD 14%), respectively, and in the CCRT+TMZ group, they were 50% (SD 17%) and 0%, respectively. The log-rank test in PFS between the two groups was not statistically significant. Conclusions: In this study, CCRT with TMZ followed by adjuvant TMZ did not result in a better outcome when compared with RT alone followed by adjuvant TMZ. In addition, TMZ either as adjuvant therapy or as CCRT did not improve the prognosis of the patients with newly diagnosed diffuse brainstem glioma.

Original languageEnglish
Pages (from-to)1035-1041
Number of pages7
JournalChild's Nervous System
Volume26
Issue number8
DOIs
Publication statusPublished - Aug 1 2010
Externally publishedYes

Fingerprint

temozolomide
Glioma
Brain Stem
Disease-Free Survival
Radiotherapy
Disease Progression
Therapeutics
Radiation
Veterans Hospitals
Chemoradiotherapy
General Hospitals

Keywords

  • Adjuvant chemotherapy
  • Concomitant chemoradiotherapy
  • Diffuse brainstem glioma
  • Overall survival
  • Progression-free survival
  • Radiotherapy
  • Temozolomide

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children : Experience at a single institution. / Chiang, Kuo Liang; Chang, Kai Ping; Lee, Yi Yen; Huang, Pin I.; Hsu, Ting Rong; Chen, Yi Wei; Chang, Feng Chi; Wong, Tai-Tong.

In: Child's Nervous System, Vol. 26, No. 8, 01.08.2010, p. 1035-1041.

Research output: Contribution to journalArticle

Chiang, Kuo Liang ; Chang, Kai Ping ; Lee, Yi Yen ; Huang, Pin I. ; Hsu, Ting Rong ; Chen, Yi Wei ; Chang, Feng Chi ; Wong, Tai-Tong. / Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children : Experience at a single institution. In: Child's Nervous System. 2010 ; Vol. 26, No. 8. pp. 1035-1041.
@article{1548953cb21f49699b33c06e409d0093,
title = "Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: Experience at a single institution",
abstract = "Purpose: The purpose of this study was to assess the efficacy of TMZ on diffuse brainstem glioma, either concomitant with radiotherapy or as an adjuvant treatment after radiotherapy in children. Methods and materials: Eighteen children (median age at diagnosis was 8.3 years) meet the following criteria: (1) newly diagnosed diffuse brainstem glioma; (2) aged less than 18 years old, which were treated with TMZ at Taipei Veterans General Hospital from January 2004 to December 2008. They were divided into two groups according to treatment modalities: a radiotherapy alone followed by adjuvant TMZ (RT+TMZ) group received conventional radiation after initial diagnosis, and a concomitant chemoradiotherapy followed by adjuvant TMZ (CCRT+TMZ) group received concurrent chemotherapy during radiation with TMZ (75 mg/M2/day). After completion of the radiotherapy, TMZ (150 mg/M2) was administered once per day for five consecutive days for all enrolled patients in each 28-day cycle. We evaluated the progression-free survival in both groups of patients. Results: There were 10 patients in RT+TMZ group and eight in CCRT+TMZ group. All patients experienced progression of disease. Twelve patients (75{\%}) died, and all deaths were attributed to the disease progression. The median progression-free survival (PFS) was 7.4 months for the RT+TMZ group and 6.4 months for the CCRT+TMZ group. The 6-month and 1-year PFS in the RT+TMZ group were 70{\%} (SD 14{\%}) and 30{\%} (SD 14{\%}), respectively, and in the CCRT+TMZ group, they were 50{\%} (SD 17{\%}) and 0{\%}, respectively. The log-rank test in PFS between the two groups was not statistically significant. Conclusions: In this study, CCRT with TMZ followed by adjuvant TMZ did not result in a better outcome when compared with RT alone followed by adjuvant TMZ. In addition, TMZ either as adjuvant therapy or as CCRT did not improve the prognosis of the patients with newly diagnosed diffuse brainstem glioma.",
keywords = "Adjuvant chemotherapy, Concomitant chemoradiotherapy, Diffuse brainstem glioma, Overall survival, Progression-free survival, Radiotherapy, Temozolomide",
author = "Chiang, {Kuo Liang} and Chang, {Kai Ping} and Lee, {Yi Yen} and Huang, {Pin I.} and Hsu, {Ting Rong} and Chen, {Yi Wei} and Chang, {Feng Chi} and Tai-Tong Wong",
year = "2010",
month = "8",
day = "1",
doi = "10.1007/s00381-010-1106-1",
language = "English",
volume = "26",
pages = "1035--1041",
journal = "Child's Nervous System",
issn = "0256-7040",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children

T2 - Experience at a single institution

AU - Chiang, Kuo Liang

AU - Chang, Kai Ping

AU - Lee, Yi Yen

AU - Huang, Pin I.

AU - Hsu, Ting Rong

AU - Chen, Yi Wei

AU - Chang, Feng Chi

AU - Wong, Tai-Tong

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Purpose: The purpose of this study was to assess the efficacy of TMZ on diffuse brainstem glioma, either concomitant with radiotherapy or as an adjuvant treatment after radiotherapy in children. Methods and materials: Eighteen children (median age at diagnosis was 8.3 years) meet the following criteria: (1) newly diagnosed diffuse brainstem glioma; (2) aged less than 18 years old, which were treated with TMZ at Taipei Veterans General Hospital from January 2004 to December 2008. They were divided into two groups according to treatment modalities: a radiotherapy alone followed by adjuvant TMZ (RT+TMZ) group received conventional radiation after initial diagnosis, and a concomitant chemoradiotherapy followed by adjuvant TMZ (CCRT+TMZ) group received concurrent chemotherapy during radiation with TMZ (75 mg/M2/day). After completion of the radiotherapy, TMZ (150 mg/M2) was administered once per day for five consecutive days for all enrolled patients in each 28-day cycle. We evaluated the progression-free survival in both groups of patients. Results: There were 10 patients in RT+TMZ group and eight in CCRT+TMZ group. All patients experienced progression of disease. Twelve patients (75%) died, and all deaths were attributed to the disease progression. The median progression-free survival (PFS) was 7.4 months for the RT+TMZ group and 6.4 months for the CCRT+TMZ group. The 6-month and 1-year PFS in the RT+TMZ group were 70% (SD 14%) and 30% (SD 14%), respectively, and in the CCRT+TMZ group, they were 50% (SD 17%) and 0%, respectively. The log-rank test in PFS between the two groups was not statistically significant. Conclusions: In this study, CCRT with TMZ followed by adjuvant TMZ did not result in a better outcome when compared with RT alone followed by adjuvant TMZ. In addition, TMZ either as adjuvant therapy or as CCRT did not improve the prognosis of the patients with newly diagnosed diffuse brainstem glioma.

AB - Purpose: The purpose of this study was to assess the efficacy of TMZ on diffuse brainstem glioma, either concomitant with radiotherapy or as an adjuvant treatment after radiotherapy in children. Methods and materials: Eighteen children (median age at diagnosis was 8.3 years) meet the following criteria: (1) newly diagnosed diffuse brainstem glioma; (2) aged less than 18 years old, which were treated with TMZ at Taipei Veterans General Hospital from January 2004 to December 2008. They were divided into two groups according to treatment modalities: a radiotherapy alone followed by adjuvant TMZ (RT+TMZ) group received conventional radiation after initial diagnosis, and a concomitant chemoradiotherapy followed by adjuvant TMZ (CCRT+TMZ) group received concurrent chemotherapy during radiation with TMZ (75 mg/M2/day). After completion of the radiotherapy, TMZ (150 mg/M2) was administered once per day for five consecutive days for all enrolled patients in each 28-day cycle. We evaluated the progression-free survival in both groups of patients. Results: There were 10 patients in RT+TMZ group and eight in CCRT+TMZ group. All patients experienced progression of disease. Twelve patients (75%) died, and all deaths were attributed to the disease progression. The median progression-free survival (PFS) was 7.4 months for the RT+TMZ group and 6.4 months for the CCRT+TMZ group. The 6-month and 1-year PFS in the RT+TMZ group were 70% (SD 14%) and 30% (SD 14%), respectively, and in the CCRT+TMZ group, they were 50% (SD 17%) and 0%, respectively. The log-rank test in PFS between the two groups was not statistically significant. Conclusions: In this study, CCRT with TMZ followed by adjuvant TMZ did not result in a better outcome when compared with RT alone followed by adjuvant TMZ. In addition, TMZ either as adjuvant therapy or as CCRT did not improve the prognosis of the patients with newly diagnosed diffuse brainstem glioma.

KW - Adjuvant chemotherapy

KW - Concomitant chemoradiotherapy

KW - Diffuse brainstem glioma

KW - Overall survival

KW - Progression-free survival

KW - Radiotherapy

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=77956181833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956181833&partnerID=8YFLogxK

U2 - 10.1007/s00381-010-1106-1

DO - 10.1007/s00381-010-1106-1

M3 - Article

VL - 26

SP - 1035

EP - 1041

JO - Child's Nervous System

JF - Child's Nervous System

SN - 0256-7040

IS - 8

ER -